Logo-jcvtr
Submitted: 06 Oct 2016
Revision: 21 Mar 2017
Accepted: 22 Mar 2017
ePublished: 04 May 2017
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Cardiovasc Thorac Res. 2017;9(2): 71-77.
doi: 10.15171/jcvtr.2017.12
PMID: 28740625
PMCID: PMC5516054
  Abstract View: 1712
  PDF Download: 1048

Original Article

Pulmonary valve replacement in patients with corrected tetralogy of Fallot

Fotios M. Mitropoulos 1, Meletios A. Kanakis 1, Christos Ntellos 2, Constantinos Loukas 3, Periklis Davlouros 4, Theophili Kousi 1, Andrew C. Chatzis 4*

1 Department of Pediatric and Congenital Cardiac Surgery, Onassis Cardiac Surgery Center, Athens, Greece
2 Department of Cardiology, Tzaneio General Hospital, Piraeus, Greece
3 Department of Medical Physics, Medical School, National and Kapodistrian University of Athens, Greece
4 Department of Cardiology, University General Hospital of Patras, Greece
*Corresponding Author: Email: achatzis1955@gmail.com

Abstract

Introduction: Development of pulmonary insufficiency in patients with surgically corrected tetralogy of Fallot (TOF) may lead to severe right heart failure with serious consequences. We herein present our experience with pulmonary valve replacement (PVR) in these patients.
Methods: From 2005-2013, 99 consecutive patients (71 males/28 females, mean age 38±8 years), underwent PVR after 7 to 40 (mean 29 ± 8) years from the initial correction. Seventy nine of the symptomatic patients presented in NYHA II, 14 in III and 2 in IV. All underwent PVR with a stented bioprosthetic valve, employing a beating heart technique with normothermic extracorporeal circulation support.  Concomitant procedures included resection of aneurysmal outflow tract patches (n = 37), tricuspid valve annuloplasty (n = 36), augmentation of stenotic pulmonary arteries (n = 9), maze procedure (n = 2) and pulmonary artery stenting (n = 4).
Results:
There were 2 perioperative deaths (2%). One patient developed sternal dehiscence requiring rewiring.  Median ICU and hospital stay was 1 and 7 days respectively. Postoperative echocardiography at 6 and 12 months showed excellent bioprosthetic valve performance, significant decrease in size of the right cardiac chambers and reduction of tricuspid regurgitation  (TR) in the majority of the patients.  At mean follow-up of 3.6 ± 2 years, all surviving patients remain in excellent clinical condition.
Conclusion: 
Probability of reoperation for pulmonary insufficiency in patients with surgically corrected TOF increases with time and timely PVR by preventing the development of right heart failure is crucial for long-term survival.  Current bioprosthetic valve technology in combination with the beating heart technique provides excellent immediate and short-term results. Further follow-up is necessary to evaluate long-term outcome.
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 1713

Your browser does not support the canvas element.


PDF Download: 1048

Your browser does not support the canvas element.